SNY Forex News
Sanofi To Invest $1.05 Bln For New Insulin Production Base In China
French drug major Sanofi plans to invest around 1 billion euros or about $1.05 billion to build a new insulin manufacturing base in Beijing, China, reports said. The move represents Sanofi's single largest investment in China so far, where it has been present for more than 40 years. The investment will boost the manufacturing of insulin to help diabetic patients in the region.
RTTNews
|
1 day ago
Sanofi And Biovac Ink Manufacturing Partnership To Make Inactivated Polio Vaccines In Africa
French drug major Sanofi (SNYNF, SNY) and South African biopharmaceutical company Biovac Institute (Pty) Ltd. announced Thursday their local manufacturing partnership to produce inactivated polio vaccines (IPV) in Africa.
RTTNews
|
167 days ago
Sanofi, OpenAI To Build AI Software To Boost Drug Development
French drug major Sanofi is teaming with artificial intelligence or AI startup OpenAI, the developer of highly popular generative AI chatbot ChatGPT, as well as Formation Bio, an AI and tech-driven drug developer, to build AI-powered software to accelerate drug development and bring new medicines more efficiently.
RTTNews
|
197 days ago
Sanofi Q1 Profit Weak, But Sales Rise; Backs FY24 View; Stock Up
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq.
RTTNews
|
223 days ago
Sanofi Q3 Profit Rises, Backs FY23 View, To Split Consumer Healthcare Unit; Stock Dips
French drug major Sanofi reported Friday higher profit in its third quarter, while sales declined. Further, the company reiterated fiscal 2023 business earnings view.
Separately, Sanofi said it plans to separate the Consumer Healthcare Business with a view to focus on Biopharma business. Sanofi shares were losing more than 15 percent in the morning trading in Paris.
RTTNews
|
404 days ago
Sanofi Q4 Profit Climbs, Sees Slower Earnings Growth In FY23; Stock Down
French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
RTTNews
|
670 days ago
Regeneron Completes Acquiring Sanofi's Stake In Libtayo
Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that it has completed the acquisition of French drug major Sanofi's (SNYNF, SNY) stake in Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.
RTTNews
|
887 days ago
